Researchers at Cincinnati Children's Hospital Medical Center, Kurome Therapeutics Inc. and the U.S. Department of Health and Human Services have disclosed IL-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 and/or FLT3 (FLK2/STK1) inhibitors reported to be useful for the treatment of cancer, autoimmune and inflammatory disorders.
Protego Biopharma Inc. has identified prodrugs of transthyretin (TTR; PALB) stabilizers acting as TTR aggregation and/or amyloid formation inhibitors reported to be useful for the treatment of familial amyloid polyneuropathy and familial amyloid cardiomyopathy.
PTC Therapeutics Inc. has synthesized heteroaryl compounds acting as huntingtin (HTT) (mutant) expression inhibitors reported to be useful for the treatment of Huntington's disease.
Gate Bioscience Inc. has disclosed protein transport protein Sec61 complex inhibitors reported to be useful for the treatment of cancer, viral infections, malaria, prion infection, light chain amyloidosis, autoimmune diseases and renal and urinary system genetic disorders.
Neurocrine Biosciences Inc. has described new muscarinic M4 receptor antagonists reported to be useful for the treatment of tremor, dystonia and parkinsonism.
Beigene Co. Ltd. has divulged proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase binding moiety covalently linked to a mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1)-targeting moiety reported to be useful for the treatment of cancer.
Grey Wolf Therapeutics Ltd. has identified phenyl-sulfamoyl-benzoic acid derivatives acting as endoplasmic reticulum aminopeptidase 1 (ERAP1) inhibitors reported to be useful for the treatment of cancer, viral infection, inflammatory and immunological disorders.
Hebei Feinisi Biotechnology Co. Ltd. has synthesized shared epitope-containing HLA DR molecule (SE-DR) affinity peptides reported to be useful for the treatment of rheumatic diseases.
RSS